The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The main difference is BNT327 targets PD-L1 while ivonescimab ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...